Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Posts Quarterly Earnings Results, Meets Expectations

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) issued its earnings results on Tuesday. The company reported $0.30 earnings per share for the quarter, meeting the consensus estimate of $0.30, FiscalAI reports. Kiniksa Pharmaceuticals International had a net margin of 9.69% and a return on equity of 13.26%. The business had revenue of $243.60 million for the quarter, compared to the consensus estimate of $226.49 million.

Here are the key takeaways from Kiniksa Pharmaceuticals International’s conference call:

• ARCALYST revenue rose 55% year over year to $243.6 million in Q2 2026, an increase of more than $29 million sequentially. Management raised full-year revenue guidance to $980 million–$995 million from $930 million–$945 million.
• Commercial momentum strengthened, with approximately 450 new prescribers and 150 additional repeat prescribers added during the quarter. ARCALYST penetration in the multiple-recurrence population reached approximately 21%, leaving substantial room for expansion.
• Kiniksa advanced KPL-387 into the pivotal PASTEURAL Phase III trial in recurrent pericarditis, evaluating a 300 mg monthly dose after Phase II data showed rapid and sustained treatment response. The company anticipates a potential launch in 2028–2029.
• KPL-387’s Phase II data showed median treatment response in four days and CRP normalization in eight days, with tolerability consistent with IL-1 pathway inhibition; however, the disclosed analysis was interim and detailed follow-up information remained limited.
• Operating income was $27.2 million, net income was $25.4 million, and quarter-end cash was $525.9 million after approximately $58 million of net cash generation. Collaboration profit increased 68% year over year to $176.1 million despite continued investments in commercialization and clinical development.

Kiniksa Pharmaceuticals International Stock Up 0.9%

Shares of NASDAQ:KNSA traded up $0.69 during midday trading on Wednesday, reaching $80.13. The company’s stock had a trading volume of 181,217 shares, compared to its average volume of 725,069. Kiniksa Pharmaceuticals International has a 1 year low of $29.66 and a 1 year high of $82.94. The business has a 50 day moving average price of $57.59 and a 200 day moving average price of $50.44. The firm has a market cap of $6.16 billion, a price-to-earnings ratio of 89.21 and a beta of 0.07.

Insider Transactions at Kiniksa Pharmaceuticals International

In other Kiniksa Pharmaceuticals International news, insider John F. Paolini sold 58,424 shares of the company’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $53.71, for a total transaction of $3,137,953.04. Following the completion of the sale, the insider directly owned 65,623 shares in the company, valued at $3,524,611.33. This represents a 47.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Sanj K. Patel sold 48,565 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $54.02, for a total transaction of $2,623,481.30. Following the transaction, the chief executive officer directly owned 48,565 shares in the company, valued at approximately $2,623,481.30. This trade represents a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 109,130 shares of company stock valued at $5,877,070. 51.98% of the stock is owned by company insiders.

Institutional Trading of Kiniksa Pharmaceuticals International

A number of hedge funds have recently made changes to their positions in the company. Virtu Financial LLC acquired a new position in shares of Kiniksa Pharmaceuticals International during the fourth quarter worth $267,000. Invesco Ltd. increased its stake in Kiniksa Pharmaceuticals International by 25.9% during the 4th quarter. Invesco Ltd. now owns 32,334 shares of the company’s stock worth $1,334,000 after buying an additional 6,656 shares during the period. Mercer Global Advisors Inc. ADV lifted its holdings in Kiniksa Pharmaceuticals International by 7.1% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 7,684 shares of the company’s stock worth $317,000 after buying an additional 508 shares in the last quarter. Empowered Funds LLC purchased a new position in Kiniksa Pharmaceuticals International in the 4th quarter valued at about $51,000. Finally, XTX Topco Ltd acquired a new stake in shares of Kiniksa Pharmaceuticals International during the fourth quarter valued at about $291,000. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently weighed in on KNSA. Canaccord Genuity Group lifted their price target on Kiniksa Pharmaceuticals International from $62.00 to $64.00 and gave the company a “buy” rating in a research note on Wednesday, April 29th. Wedbush lifted their price target on Kiniksa Pharmaceuticals International from $59.00 to $72.00 and gave the stock an “outperform” rating in a research note on Monday, June 29th. Wells Fargo & Company increased their price objective on shares of Kiniksa Pharmaceuticals International from $57.00 to $74.00 and gave the company an “overweight” rating in a research note on Monday, July 13th. Citigroup raised their target price on shares of Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the company a “buy” rating in a report on Wednesday. Finally, Zacks Research raised shares of Kiniksa Pharmaceuticals International from a “hold” rating to a “strong-buy” rating in a report on Wednesday, June 17th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $73.71.

Key Headlines Impacting Kiniksa Pharmaceuticals International

Here are the key news stories impacting Kiniksa Pharmaceuticals International this week:

• Positive Sentiment: Revenue and guidance exceeded expectations. Second-quarter revenue was $243.6 million, above the $226.5 million consensus estimate. Kiniksa also raised its 2026 ARCALYST net-product-revenue outlook to $980 million-$995 million, well above the approximately $940.1 million analyst consensus. Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution
• Positive Sentiment: ARCALYST momentum remained strong. The company reported approximately 55% year-over-year growth in second-quarter ARCALYST net product revenue, supporting expectations for continued commercial expansion. Kiniksa Pharmaceuticals Q2 Earnings Match Estimates
• Positive Sentiment: Pipeline developments improved the long-term outlook. Phase 2 testing of KPL-387 showed rapid and sustained reductions in pain and inflammation at the monthly 300-milligram dose selected for Phase 3. The pivotal Phase 3 recurrent-pericarditis trial has begun enrolling and dosing patients. Kiniksa Portfolio Execution Update
• Neutral Sentiment: Profitability was solid, but the earnings result was largely expected. Adjusted or GAAP EPS was $0.30, matching consensus estimates and rising from $0.23 a year earlier. The revenue beat and guidance increase were therefore more significant catalysts than the bottom-line result. Kiniksa Q2 Earnings and Revenue Report
• Negative Sentiment: Valuation and execution risks remain. With KNSA trading near its 52-week high and at a relatively elevated price-to-earnings ratio, investors may expect continued strong ARCALYST growth and successful KPL-387 clinical execution. Any slowdown or disappointing trial data could increase volatility.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1? blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.